

PRINTED DATE/TIME: 9/12/2022 11:10

PATIENT NAME	PATIENT ID	REQ NUMBER	CLIENT	COPIES
CASPARI, JENNIFER	AAQH4212	321644337	Parra, Melissa, CNP	1

The information contained in this message is confidential information intended ONLY for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state law. If you have received this communication in error, PLEASE NOTIFY US IMMEDIATELY by telephone and shred/delete the original message.

Distribution: #EMAIL_jenharsh@gmail.com#



Ordering Provider: MELISSA PARRA, CN	ND.	Patient Name:	CASP	ARI, JENNI	FER	
WELISSA PARRA, CI	NP	Patient ID (MRN):	AAQH4212	Client P	ΓID (MRN):	:
		Date of Birth:	3/30/1983	Sex: F A	ge: 39Y	
Location: ONS;1		Patient Phone #:	(808) 778-725	3		
Requisition#:	Report Status:	Collection Date/Time:	,	Receive Date/Ti		
321644337	FINAL	09/05/2022 08:46		09/05/2022	1	1
Test Name	Flag	Result		Ref Range	Units	Lab
CBC						
WBC		4.5		4.0-11.0	x10E3/uL	{TC}
RBC		4.37		4.01-5.47	x10E6/uL	{TC}
Hgb		13.3		12.0-16.0	gm/dL	{TC}
Hct		40		36-48	%	{TC}
MCV		92		81-101	fL	{TC}
MCHC		32.9		31.1-35.5	gm/dL	{TC}
RDW		12.0		11.0-14.5	%	{TC}
Platelets		272		150-400	x10E3/uL	{TC}
DIFFERENTIAL		Auto Diff				{TC}
Diff Type					0/	{TC}
Neutrophils		53			%	
Lymphocytes		37			%	{TC}
Monocytes		9			%	{TC}
Eosinophils		0			%	{TC}
Basophils		1			%	{TC}
Abs. Neutrophil		2.3		1.8-7.0	x10E3/uL	{TC}
Abs. Lymphocyte		1.7		1.0-3.4	x10E3/uL	{TC}
Abs. Monocyte		0.4		0.2-0.8	x10E3/uL	{TC}
Abs. Eosinophil		0.0		0.0-0.3	x10E3/uL	{TC}
Abs. Basophil		0.1		0.0-0.1	x10E3/uL	{TC}
DHEA-Sulfate		111		61-337	ug/dL	{TC}
DILLA Guilate	New method ar	nd reference range	effective		ug/uL	
Celiac Disease Panel						
IgA	•	Sufficient				{TC}
Gliadin IgA Ab		<0.2		0.0-14.9	U/mL	{TC}
Tis.Transglut.Ab	lgA	<0.5		0.0-14.9	U/mL	{TC}
Ŭ	The tissue tr for celiac di increase the Patients must	ansglutaminase (t sease. The deamid sensitivity of tT be on a gluten-c eliac disease.	ated gliadi G IgA with	n peptide (I a slight de	OGP) IgA tes crease in s	st can becificity.
Homocysteine		7.9		0.0-15.0	umol/L	{TC}
	for suspected errors of met Measurement of and folate de Treatment res	of methylmalonic a eficiencies, as MM sponse can be eval	ciencies (v cid (MMA) d A is only e uated by mo	ritamin B12, distinguishe Devated in Onitoring pl	folate) an s between v vitamin B12	d inborn itamin B12 deficiency.

Ordering Provider: MELISSA PARRA, CNP		Patient Name:	CASP	ARI, JENN	IFER	
WELISSA PARRA, CI	iF	Patient ID (MRN):	AAQH4212	Client F	PT ID (MRN):	:
		Date of Birth:	3/30/1983	Sex: F A	ge: 39Y	
Location: ONS;1		Patient Phone #:	(808) 778-725	3		
Requisition#:	Report Status:	Collection Date/Time:	,	Receive Date/	Γime:	
321644337	FINAL	09/05/2022 08:46		09/05/2022		
Test Name		Flag Result		Ref Range	Units	Lab
CRP High Sensitivity		0.9		0.0-3.0	mg/L	{TC}
	guideline Risk Low Avera High Optimally	hsCRP (mg/L) 	o hsCRP resul	ts obtained	-	
Lipid Panel						
Triglyceride		91		<150	mg/dL	{TC}
	etiology.		uires furthe			-
Cholesterol	etiology.	nfasting triglycerid fasting lipid panel		ion is grea recommende	iter than o	-
Cholesterol HDI	etiology.	nfasting triglycerid fasting lipid panel		ion is grea recommende <200	iter than o ed. mg/dL	r equal to 500
Cholesterol HDL LDL(calc)	etiology. If the no mg/dL, a	nfasting triglycerid fasting lipid panel 172 59 95		ion is grea recommende	iter than o	r equal to 500
HDL	Total Cho <200 mg/dL, a Total Cho <200 mg/d 200-239 m >239 mg/d Triglycer <150 mg/d 150-159 m 200-499 m >499 mg/d HDL Chole Males: >3 Females: LDL Chole <100 mg/d 100-129 m 130-159 m	nfasting triglycerid fasting lipid panel 172 59 95 lesterol L (Desirable) g/dL (Borderline Hig L (High) ides L (Normal) g/dL (Borderline Hig g/dL (High) L (Very High) sterol 9 mg/dL (Desirable) >49 mg/dL (Desirable)	le concentrat is strongly wh) h)	ion is grea recommende <200 >40	mg/dL mg/dL	r equal to 500
HDL	Total Cho <200 mg/dL, a Total Cho <200 mg/d 200-239 m >239 mg/d Triglycer <150 mg/d 150-159 m 200-499 m >499 mg/d HDL Chole Males: >3 Females: LDL Chole <100 mg/d 100-129 m 130-159 m 160-189 m >189 mg/d	nfasting triglycerid fasting lipid panel 172 59 95 lesterol L (Desirable) g/dL (Borderline High L (Normal) g/dL (Borderline High L (Very High) sterol 9 mg/dL (Desirable) >49 mg/dL (Desirable) >49 mg/dL (Desirable) sterol L (Desirable) g/dL (Above Desirable) g/dL (Borderline High L (High)	le concentrat is strongly wh) h)	ion is grea recommende <200 >40	mg/dL mg/dL	r equal to 500 {TC} {TC}
HDL LDL(calc)	Total Cho <200 mg/dL, a Total Cho <200 mg/d 200-239 m >239 mg/d Triglycer <150 mg/d 150-159 m 200-499 m >499 mg/d HDL Chole Males: >3 Females: LDL Chole <100 mg/d 100-129 m 130-159 m 160-189 m >189 mg/d	nfasting triglycerid fasting lipid panel 172 59 95 lesterol L (Desirable) g/dL (Borderline High L (Normal) g/dL (Borderline High L (Very High) sterol 9 mg/dL (Desirable) >49 mg/dL (Desirable) >49 mg/dL (Desirable) sterol L (Desirable) g/dL (Above Desirable) g/dL (Borderline High L (High)	le concentrat is strongly wh) h)	ion is grea recommende <200 >40	mg/dL mg/dL	r equal to 500 {TC} {TC}
HDL LDL(calc) Comp Metabolic Pane	Total Cho <200 mg/dL, a Total Cho <200 mg/d 200-239 m >239 mg/d Triglycer <150 mg/d 150-159 m 200-499 m >499 mg/d HDL Chole Males: >3 Females: LDL Chole <100 mg/d 100-129 m 130-159 m 160-189 m >189 mg/d	nfasting triglycerid fasting lipid panel 172 59 95 lesterol L (Desirable) g/dL (Borderline High L (High) ides L (Normal) g/dL (Borderline High L (Very High) sterol 9 mg/dL (Desirable) >49 mg/dL (Desirable) >49 mg/dL (Desirable) sterol L (Desirable) g/dL (Above Desirable) g/dL (Borderline High L (Very High) L (Very High) Sterol L (Desirable) g/dL (Above Desirable) g/dL (Borderline High L (Very High) L (Very High)	le concentrat is strongly wh) h)	<pre><200</pre>	mg/dL mg/dL mg/dL	r equal to 500 {TC} {TC} {TC}
HDL LDL(calc) Comp Metabolic Pane Sodium	Total Cho <200 mg/dL, a Total Cho <200 mg/d 200-239 m >239 mg/d Triglycer <150 mg/d 150-159 m 200-499 m >499 mg/d HDL Chole Males: >3 Females: LDL Chole <100 mg/d 100-129 m 130-159 m 160-189 m >189 mg/d	nfasting triglycerid fasting lipid panel 172 59 95 lesterol L (Desirable) g/dL (Borderline High L (High) ides L (Normal) g/dL (Borderline High L (Very High) sterol 9 mg/dL (Desirable) >49 mg/dL (Desirable) >49 mg/dL (Desirable) sterol L (Desirable) g/dL (Above Desirable) g/dL (Borderline High L (Very High) L (Very High) 140	le concentrat is strongly wh) h)	<pre></pre>	mg/dL mg/dL mg/dL mg/dL	(TC) (TC) (TC) (TC)



Ordering Provider: MELISSA PARRA, CNP		Patient Name:	CASP	ARI, JENN		
WELISSA FARRA, CIVI	-	Patient ID (MRN):	AAQH4212	Client F	PT ID (MRN):	:
		Date of Birth:	3/30/1983	Sex: F A	ige: 39Y	
Location, ONG:4		Patient Phone #:			.9	
Location: ONS;1 Requisition#:	Report Status:	Collection Date/Time:	(808) 778-725	Receive Date/	Гіme:	
321644337	FINAL	09/05/2022 08:46		09/05/2022	14:45	
Test Name	Flag	Result		Ref Range		Lab
Anion Gap		10		<18	mmol/L	{TC}
Glucose		84		60-100	mg/dL	{TC}
BUN	L	5		7-20	mg/dL	{TC}
Creatinine		0.56		0.50-0.90	mg/dL	{TC}
eGFR non-African		119		>60	mL/min/1.73	
	The eGFR 1s not use a ra	calculated using ce coefficient.	the 2021 CKD	-EPI creati	nine equati	on that does
GFR Comment						{TC}
Of It Commont	An eGFR base	d on creatinine c	oncentration	is only us	seful when i	enal function
	is stable. I	t is not suitable ns or extremes in	for individ	uals with u	ınstable cre	eatinine
Calcium		9.0		8.6-10.0	mg/dL	{TC}
Total Protein		6.3		6.1-8.2	gm/dL	{TC}
Albumin		3.6		3.5-5.2	gm/dL	{TC}
Globulin		2.7		2.4-4.2	gm/dL	{TC}
Bilirubin, total		0.4		0.0-1.2	mg/dL	{TC}
Alk Phos		64		35-104	U/L	{TC}
AST(SGOT)		22		10-35	U/L	{TC}
ALT(SGPT)		17		10-35	U/L	{TC}
C-Reactive Protein		<0.3		<0.5	mg/dL	{TC}
Iron and TIBC						
Iron		108		37-145	ug/dL	{TC}
UIBC		217			ug/dL	{TC}
TIBC		325		250-450	ug/dL	{TC}
Iron Sat.		33		20-55	%	{TC}
Ferritin		16		12-160	ng/mL	{TC}
FSH		10.1			mIU/mL	{TC}
	Follicular p Ovulation: 4 Luteal phase Postmenopaus	ence Interval: hase: 3.4-12.5 mI .7-21.5 mIU/mL : 1.7-7.7 mIU/mL al: 25.8-134.8 mI	U/mL	07/10/2222		
	New method a	nd reference rang	e errective	07/18/2022	•	
Vitamin B12/S.Folate						
Vitamin B12	New method a	382 nd reference rang	e effective	232-1245 07/18/2022 .	pg/mL	{TC}
				, -, <u>-</u>		
Serum Folate		31.7		4.6-34.8	ng/mL	{TC}

MILLINSA PARRA IN	AID.	Patient Name: CASPARI, JENNIFER				
MELISSA PARRA, CN	NP	Patient ID (MRN): AAQH		AQH4212 Client PT ID (MRN): :		
		Date of Birth:	3/30/1983	Sex: F A	.ge: 39Y	
Location: ONS;1		Patient Phone #:	(808) 778-725		J	
Requisition#:	Report Status:	Collection Date/Time:	(600) 116-123	Receive Date/	Γime·	
321644337	FINAL	09/05/2022 08:46		09/05/2022		
Test Name	Flag	Result		Ref Range	Units	Lab
Vitamin D,25-Hydrox	v					
Vitamin D Scrn	,	30		30-100	ng/mL	{TC}
Vitamin D Status		Sufficient			<u>J</u> -	{TC}
Cortisol	Morning (6am- Afternoon (4p Test performe	9.6 erence Interval: -10am): 6.0-18.4 om-10pm): 2.7-10. ed by Roche Corti nd reference rang	5 ug/dL sol electroc	hemilumine 07/18/2022	ug/dL scent immun	(TC)
ANA Screen		Negative		Negative		{TC}
CA 125		16		<39	U/mL	{TC}
	values in the in patients v be interprete disease.	n confirmed ovari e same range as h vith nonmalignant ed as absolute ev nd reference rang	ealthy indiv disease. The didence of the	iduals. El erefore, a e presence	evations ma CA 125 val or absence	y be observed ue should not
Insulin		4.1		2.6-24.9	uIU/mL	{TC}
	non-fasting s concentration aspart, insu	cerval is based of camples, insuling in a cample is no cr	n samples ob	tained in	the fasting	
	Ref: Ann. Cli	7 900% cross-reac n. Biochem. 2015 nd reference rang	oss-reactivi sulin lispro tivity with s: 52(3): 321	ty with the sum of the	e analogues lin detemir argine.	the glucose insulin
Free T3	Ref: Ann. Clar New method ar	/ 900% cross-reac in. Biochem. 2015	ross-reactivi Isulin lispro Etivity with Is 52(3): 321 The effective	ty with the and insuling line and insuling line also on a second control of the second c	e analogues lin detemir argine. pg/mL	the glucose insulin
Free T3 Anti-TPO-Ab	Ref: Ann. Clar New method ar	y 900% cross-reac n. Biochem. 2015 nd reference rang	ross-reactivi Isulin lispro Etivity with Is 52(3): 321 The effective	ty with the and insuling line and insuling line also on a second control of the second c	e analogues lin detemir argine. pg/mL	the glucose insulin . There is
	Ref: Ann. Clane New method ar	y 900% cross-reace n. Biochem. 2015 nd reference rang 3.4 nd reference rang	ross-reactivi isulin lispro itivity with i: 52(3): 321 ge effective	ty with the and insulin glands. o7/18/2022 2.0-4.4 07/18/2022 <35 0.9-1.7	e analogues lin detemir argine. pg/mL IU/mL	the glucose insulin . There is
Anti-TPO-Ab	New method ar New method ar	y 900% cross-reaction. Biochem. 2015 and reference range 3.4 and reference range <15	ross-reactivi isulin lispro itivity with i: 52(3): 321 ge effective ge effective	ty with the and insulin glands. o7/18/2022 2.0-4.4 07/18/2022 <35 0.9-1.7 07/18/2022	pg/mL IU/mL ng/dL uIU/mL	the glucose insulin . There is {TC}

Ordering Provider: MELISSA PARRA, CNP		Patient Name:	CASPA	RI, JEN	NIFER	
WELISSA PARRA, CI	vr	Patient ID (MRN):	AAQH4212	Client	t PT ID (MRN):	:
		Date of Birth:	3/30/1983 S	ex: F	Age: 39Y	
Location: ONS;1		Patient Phone #:	(808) 778-7253	}		
Requisition#:	Report Status:	Collection Date/Time:		Receive Date		
321644337 Test Name	FINAL	09/05/2022 08:46 Flag Result		09/05/202	22 14:45 ge Units	Lab
	the ad concen	nce interval is for non- ministration of oral cor trations. thod and reference range	itraceptives	nales. Pr can incr	egnancy, lac ease prolact	tation, and in
Hemoglobin A1C						
Hgb A1C		5.0		4.4-5.6	%	{TC}
Est. Avg. Glucose)	97		79.6-114	.0 mg/dL	{TC}
Zinc Serum		80.8		60.0-120	.0 ug/dL	{AR}
	specim Circul and ar with pregna fastin absorp This t determ approv perfor Clinior For Ch	ed levels of serum/plasmen collected in a certifating zinc concentration e depressed with malnutinfection, inflammation, ncy. Zinc may be elevated. Zinc concertion. est was developed and it ined by ARUP Laboratoriced by the US Food and Domed in a CLIA certified al purposes. med By: ARUP Laboratoriced by the US Isood and Domed in a CLIA certified al purposes. med By: ARUP Laboratoriced by the US Isood and Domed By: ARUP Laboratoriced By: ARUP Laboratoriced Isood By: ARUP Laboratoriced Isood By: ARUP Laboratoriced By: ARU	fied metal-from are dependention. Zind stress, oral ted with zind attractions may be suffered at the suffered	ree tube lent on a may als contrac con	is recommend lbumin statu o be lowered eptives, and entation or re with copp teristics leared or his test was	ed. s er
RBC Magnesium	RBC mahomeos the suplasma RBC madecili liter This t determ approv perfor clinic Perfor	5.7 RETIVE INFORMATION: MG Fignesium results reflect tasis of magnesium. Resubmitted specimen are lysty. gnesium concentration is ter (mg/dL). To convert (mmol/L), divide the resest was developed and in ined by ARUP Laboratoriced by the US Food and Dimed in a CLIA-certified all purposes. med By: ARUP Laboratorice med By: ARUP Laboratorice way ake City, UT 84108	the intracelults may be for not property of the second or not property of the second o	Talsely lomptly somptly some milliground mile mile characted been cration. T	ores and gen ow if RBCs i eparated fro ams per limoles per teristics leared or his test was	n m

The information contained in this message is confidential information intended ONLY for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state law. If you have received this communication in error, PLEASE NOTIFY US IMMEDIATELY by telephone and shred/delete the original message.

Histamine, Plasma

Ordering Provider: MELISSA PARRA, CNP		Patient Name:	CASPA	ARI, JENNIFER	
MELIOOA I ARRA, O		Patient ID (MRN):	AAQH4212	Client PT ID (MRN): :	
		Date of Birth:	3/30/1983 S	ex: F Age: 39Y	
Location: ONS;1		Patient Phone #:	Patient Phone #: (808) 778-7253		
Requisition#:	Report Status:	Collection Date/Time	e:	Receive Date/Time:	
321644337	FINAL	09/05/2022 08:4	46	09/05/2022 14:45	
Test Name	•	Flag Result		Ref Range Units	Lab
Histamine, Plasi	na	H 13	•	0-8 nmol/L	{AR}
	determ approv perfor clinic Perfor 500 Ch Salt L	est was developed and ined by ARUP Laborato ed by the US Food and med in a CLIA certifi al purposes. med By: ARUP Laborato ipeta Way ake City, UT 84108 tory Director: Jonath	ries. It has no Drug Administr ed laboratory a ries	t been cleared or ation. This test was nd is intended for	
		ories, 1001 Woodward PL NE, Al		. CLIA 32D0534957 David Grenach	e, PhD